Vanhauwaert Dimitri, Silversmit Geert, Vanschoenbeek Katrijn, Coucke Gregory, Di Perri Dario, Clement Paul M, Sciot Raf, De Vleeschouwer Steven, Boterberg Tom, De Gendt Cindy
Department of Neurosurgery, AZ Delta hospital Roeselare, Roeselare, Belgium.
Belgian Cancer Registry, Brussels, Belgium.
J Neurooncol. 2024 Oct;170(1):79-87. doi: 10.1007/s11060-024-04776-2. Epub 2024 Aug 2.
Standard of care treatment for glioblastoma (GBM) involves surgical resection followed by chemoradiotherapy. However, variations in treatment decisions and outcomes exist across hospitals and physicians. In Belgium, where oncological care is dispersed, the impact of hospital volume on GBM outcomes remains unexplored. This nationwide study aims to analyse interhospital variability in 30-day postoperative mortality and 1-/2-year survival for GBM patients.
Data collected from the Belgian Cancer Registry, identified GBM patients diagnosed between 2016 and 2019. Surgical resection and biopsy cases were identified, and hospital case load was determined. Associations between hospital volume and mortality and survival probabilities were analysed, considering patient characteristics. Statistical analysis included logistic regression for mortality and Cox proportional hazard models for survival.
A total of 2269 GBM patients were identified (1665 underwent resection, 662 underwent only biopsy). Thirty-day mortality rates post-resection/post-biopsy were 5.1%/11.9% (target < 3%/<5%). Rates were higher in elderly patients and those with worse WHO-performance scores. No significant difference was found based on hospital case load. Survival probabilities at 1/2 years were 48.6% and 21.3% post-resection; 22.4% and 8.3% post-biopsy. Hazard ratio for all-cause death for low vs. high volume centres was 1.618 in first 0.7 year post-resection (p < 0.0001) and 1.411 in first 0.8 year post-biopsy (p = 0.0046).
While 30-day postoperative mortality rates were above predefined targets, no association between hospital volume and mortality was found. However, survival probabilities demonstrated benefits from treatment in higher volume centres, particularly in the initial months post-surgery. These variations highlight the need for continuous improvement in neuro-oncological practice and should stimulate reflection on the neuro-oncological care organisation in Belgium.
胶质母细胞瘤(GBM)的标准治疗方案包括手术切除,随后进行放化疗。然而,不同医院和医生在治疗决策和治疗结果方面存在差异。在比利时,肿瘤护理分散,医院规模对GBM治疗结果的影响仍未得到研究。这项全国性研究旨在分析GBM患者术后30天死亡率以及1年/2年生存率的医院间差异。
从比利时癌症登记处收集的数据中,确定了2016年至2019年期间诊断出的GBM患者。识别出手术切除和活检病例,并确定医院病例数量。考虑患者特征,分析医院规模与死亡率和生存概率之间的关联。统计分析包括死亡率的逻辑回归和生存率的Cox比例风险模型。
共识别出2269例GBM患者(1665例接受了切除手术,662例仅接受了活检)。切除术后/活检后的30天死亡率分别为5.1%/11.9%(目标<3%/<5%)。老年患者和世界卫生组织表现评分较差的患者死亡率更高。未发现医院病例数量与死亡率之间存在显著差异。切除术后1年/2年的生存概率分别为48.6%和21.3%;活检后为22.4%和8.3%。低容量中心与高容量中心全因死亡的风险比在切除术后的前0.7年为1.618(p<0.0001),活检后的前0.8年为1.411(p=0.0046)。
虽然术后30天死亡率高于预定义目标,但未发现医院规模与死亡率之间存在关联。然而,高容量中心的治疗在生存概率方面显示出益处,特别是在术后最初几个月。这些差异凸显了持续改善神经肿瘤学实践的必要性,并应促使人们对比利时的神经肿瘤护理组织进行反思。